<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479502</url>
  </required_header>
  <id_info>
    <org_study_id>172011</org_study_id>
    <nct_id>NCT03479502</nct_id>
  </id_info>
  <brief_title>Intra-articular Doxycycline: A Novel Treatment of Adhesive Capsulitis</brief_title>
  <acronym>DOXY</acronym>
  <official_title>Intra-articular Doxycycline: A Novel Treatment of Adhesive Capsulitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orthopedic Research and Education Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will recruit a total of 40 patients from the Vanderbilt Sports Medicine Clinics who have
      been diagnosed with adhesive capsulitis and have not undergone any previous treatment. The 40
      patients will be randomized, with 20 in the control group of 3 intra-articular injections of
      40mg Methylprednisolone spaced every two weeks, and 20 in the experimental group of 3
      intra-articular injection of 50mg doxycycline spaced every two weeks. Both groups will begin
      a standardized physical therapy program within a pain-free range of motion 4 weeks after the
      initiation of treatment. We will prospectively follow patients for one year, with follow-up
      at 6 weeks, 12 weeks, 6 months, and 12 months after the initiation of treatment.

      Outcomes will be measured using the American Shoulder and Elbow Score (ASES) and objective
      measurements of shoulder range of motion, which will be collected by the treating physician.
      Both the patients and physicians participating in the study will be blinded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adhesive capsulitis, also known as frozen shoulder, is a common condition of the shoulder
      joint affecting 2-5% of the adult population and characterized by progressive, painful loss
      of both passive and active range of motion of shoulder [1,2]. Individuals affected by this
      condition find it increasingly difficult to perform activities of daily living that require
      overhead movement or rotation of the affected shoulder. The natural history of frozen
      shoulder follows a predictable progression of symptoms, lasting from 9-24 months before
      complete resolution, and results in significant loss of productivity and quality of life for
      those affected [3]. Despite the significant number of patients affected by adhesive
      capsulitis and the extensive literature focused on the progression and natural history of the
      condition, the true underlying etiology remains poorly understood. In light of this poor
      understanding of the condition, it is not surprising that a number of conservative and
      invasive modalities exist as accepted treatments. These include non-steroidal
      anti-inflammatory drugs (NSAIDS), oral steroids, intra-articular steroid injections, Physical
      Therapy (PT), and benign neglect as well as more invasive treatments such as hydroxylation,
      manipulation under anesthesia, and arthroscopic capsular release [2]. These treatments have
      all be shown to have short-term benefit in pain relief, but none have proven to be superior
      nor alter the long-term natural history of adhesive capsulitis.

      Over the past decade, however, there has been a growing body of literature suggesting that
      Propionibacterium acnes infection may play a significant role in a variety of pathological
      conditions affecting the native shoulder, most notably frozen shoulder [4,5]. Our goal is to
      employ a treatment strategy focused on eradicating P acnes infection as a conservative
      treatment of adhesive capsulitis. Through this project, we aim to complete a prospective
      randomized pilot study to examine the hypothesis that administration of intra-articular
      antibiotics effective against P acnes will prove to be a superior treatment of adhesive
      capsulitis as compared to current gold standard of intraarticular steroid injection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients meeting the inclusion criteria will be randomized into either the control group of intra-articular injection of 40mg Methylprednisolone once every 2 two weeks for 4 weeks (day 1, week 2, week 4) or the experimental group of intraarticular injection of 50 mg doxycycline once every 2 two weeks for 4 weeks (day 1, week 2, week 4), with 20 patients in each group. Injections will be administered by the treating physician. The Vanderbilt Investigational Pharmacy will provide the doxycycline and the steroid solutions and will be in charge of patient randomization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind Masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in American Shoulder and Elbow Score (ASES)</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The ASES questionnaire was developed to provide a standardized method for evaluating shoulder function and has been validated in patients with any array of shoulder pathologies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Range of motion(ROM) measurements</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The ROM measurements will include forward flexion, abduction, external rotation at the side and at 90 degrees abduction, and internal rotation at the side and at 90 degrees abduction recorded by the treating physician at follow up visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of medical co-morbidities</measure>
    <time_frame>Baseline</time_frame>
    <description>number of medical co-morbidities per participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of symptoms</measure>
    <time_frame>Baseline</time_frame>
    <description>Length of time participants have experienced shoulder symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of participants with current dominant symptom and/or dominant symptom with disease onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain with sitting</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of patients that have pain while sitting or have ever had pain while sitting will be recorded using patient-reported survey and review of the patient's electronic medical record in Epic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stiffness</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of participants with current dominant symptom and/or dominant symptom with disease onset</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Adhesive Capsulitis</condition>
  <condition>Adhesive Capsulitis of Unspecified Shoulder</condition>
  <condition>Frozen Shoulder</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients meeting the inclusion criteria will be randomized into either the control group of intra-articular injection of 40mg Methylprednisolone once every 2 two weeks for 4 weeks (day 1, week 2, week 4) with 20 patients in each group. Injections will be administered by the treating physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients meeting the inclusion criteria will be randomized or the experimental group of intraarticular injection of 50 mg doxycycline once every 2 two weeks for 4 weeks (day 1, week 2, week 4), with 20 patients in each group. Injections will be administered by the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone Injectable Product</intervention_name>
    <description>3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <other_name>Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline Injection</intervention_name>
    <description>3 intra-articular injections of Doxycycline Injection spaced every two weeks</description>
    <arm_group_label>Doxycycline</arm_group_label>
    <other_name>Doxy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and older,

          -  diagnosis of stage II adhesive capsulitis as determined by clinical examination of the
             treating physician, and

          -  absence of abnormal findings on X-ray.

        Exclusion Criteria:

          -  allergy to Doxycycline or Methylprednisolone,

          -  pregnancy,

          -  diagnosis,

          -  Inflammatory arthritis or diabetes,

          -  secondary adhesive capsulitis (history of significant trauma, rotator cuff tear
             injury, stroke)

          -  evidence of arthritis on x-ray,

          -  current infectious disease, and

          -  any previous treatment for the for adhesive capsulitis of the affected shoulder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E Kuhn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Study Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosemary A Sanders, BA</last_name>
    <phone>615-322-7126</phone>
    <email>rosemary.a.sanders@vanderbilt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicholas J Dantzker, MD</last_name>
    <email>nicholas.j.dantzker@vanderbilt.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemary A Sanders, BA</last_name>
      <phone>615-322-7126</phone>
      <email>rosemary.a.sanders@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>John E Kuhn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas J Dantzker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hsu JE, Anakwenze OA, Warrender WJ, Abboud JA. Current review of adhesive capsulitis. J Shoulder Elbow Surg. 2011 Apr;20(3):502-14. doi: 10.1016/j.jse.2010.08.023. Epub 2010 Dec 16. Review.</citation>
    <PMID>21167743</PMID>
  </results_reference>
  <results_reference>
    <citation>Neviaser AS, Hannafin JA. Adhesive capsulitis: a review of current treatment. Am J Sports Med. 2010 Nov;38(11):2346-56. doi: 10.1177/0363546509348048. Epub 2010 Jan 28. Review.</citation>
    <PMID>20110457</PMID>
  </results_reference>
  <results_reference>
    <citation>Hannafin JA, Chiaia TA. Adhesive capsulitis. A treatment approach. Clin Orthop Relat Res. 2000 Mar;(372):95-109. Review.</citation>
    <PMID>10738419</PMID>
  </results_reference>
  <results_reference>
    <citation>Bunker TD, Boyd M, Gallacher S, Auckland CR, Kitson J, Smith CD. Association between Propionibacterium acnes and frozen shoulder: a pilot study. Shoulder Elbow. 2014 Oct;6(4):257-61. doi: 10.1177/1758573214533664. Epub 2014 May 27.</citation>
    <PMID>27582943</PMID>
  </results_reference>
  <results_reference>
    <citation>Levy O, Iyer S, Atoun E, Peter N, Hous N, Cash D, Musa F, Narvani AA. Propionibacterium acnes: an underestimated etiology in the pathogenesis of osteoarthritis? J Shoulder Elbow Surg. 2013 Apr;22(4):505-11. doi: 10.1016/j.jse.2012.07.007. Epub 2012 Sep 13.</citation>
    <PMID>22981447</PMID>
  </results_reference>
  <results_reference>
    <citation>Stirling A, Worthington T, Rafiq M, Lambert PA, Elliott TS. Association between sciatica and Propionibacterium acnes. Lancet. 2001 Jun 23;357(9273):2024-5.</citation>
    <PMID>11438138</PMID>
  </results_reference>
  <results_reference>
    <citation>Dodson CC, Craig EV, Cordasco FA, Dines DM, Dines JS, Dicarlo E, Brause BD, Warren RF. Propionibacterium acnes infection after shoulder arthroplasty: a diagnostic challenge. J Shoulder Elbow Surg. 2010 Mar;19(2):303-7. doi: 10.1016/j.jse.2009.07.065. Epub 2009 Nov 1.</citation>
    <PMID>19884021</PMID>
  </results_reference>
  <results_reference>
    <citation>Athwal GS, Sperling JW, Rispoli DM, Cofield RH. Deep infection after rotator cuff repair. J Shoulder Elbow Surg. 2007 May-Jun;16(3):306-11. Epub 2007 Feb 22.</citation>
    <PMID>17321157</PMID>
  </results_reference>
  <results_reference>
    <citation>Millett PJ, Yen YM, Price CS, Horan MP, van der Meijden OA, Elser F. Propionibacterium acnes infection as an occult cause of postoperative shoulder pain: a case series. Clin Orthop Relat Res. 2011 Oct;469(10):2824-30. doi: 10.1007/s11999-011-1767-4. Epub 2011 Jan 15.</citation>
    <PMID>21240577</PMID>
  </results_reference>
  <results_reference>
    <citation>Schneeberger AG, Yian E, Steens W. Injection-induced low-grade infection of the shoulder joint: preliminary results. Arch Orthop Trauma Surg. 2012 Oct;132(10):1387-92. Epub 2012 Jun 17.</citation>
    <PMID>22707212</PMID>
  </results_reference>
  <results_reference>
    <citation>Rollason J, McDowell A, Albert HB, Barnard E, Worthington T, Hilton AC, Vernallis A, Patrick S, Elliott T, Lambert P. Genotypic and antimicrobial characterisation of Propionibacterium acnes isolates from surgically excised lumbar disc herniations. Biomed Res Int. 2013;2013:530382. doi: 10.1155/2013/530382. Epub 2013 Aug 28.</citation>
    <PMID>24066290</PMID>
  </results_reference>
  <results_reference>
    <citation>Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, Wolfe F, Schnitzer TJ, Moreland LW, Manzi S, Bradley JD, Sharma L, Oddis CV, Hugenberg ST, Heck LW. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum. 2005 Jul;52(7):2015-25.</citation>
    <PMID>15986343</PMID>
  </results_reference>
  <results_reference>
    <citation>Aydin O, Korkusuz F, Korkusuz P, Tezcaner A, Bilgic E, Yaprakci V, Keskin D. In vitro and in vivo evaluation of doxycycline-chondroitin sulfate/PCLmicrospheres for intraarticular treatment of osteoarthritis. J Biomed Mater Res B Appl Biomater. 2015 Aug;103(6):1238-48. doi: 10.1002/jbm.b.33303. Epub 2014 Oct 28.</citation>
    <PMID>25350566</PMID>
  </results_reference>
  <results_reference>
    <citation>Haerdi-Landerer MC, Suter MM, Steiner A. Intra-articular administration of doxycycline in calves. Am J Vet Res. 2007 Dec;68(12):1324-31.</citation>
    <PMID>18052736</PMID>
  </results_reference>
  <results_reference>
    <citation>Cylwik J, Kita K, Barwijuk-Machała M, Reszeć J, Klimiuk P, Sierakowski S, Sulkowski S. The influence of doxycycline on articular cartilage in experimental osteoarthrosis induced by iodoacetate. Folia Morphol (Warsz). 2004 May;63(2):237-9.</citation>
    <PMID>15232785</PMID>
  </results_reference>
  <results_reference>
    <citation>Bernal-Lagunas R, Aguilera-Soriano JL, Berges-Garcia A, Luna-Pizarro D, Perez-Hernandez E. Haemophilic arthropathy: the usefulness of intra-articular oxytetracycline (synoviorthesis) in the treatment of chronic synovitis in children. Haemophilia. 2011 Mar;17(2):296-9. doi: 10.1111/j.1365-2516.2010.02402.x. Epub 2010 Nov 11.</citation>
    <PMID>21070486</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Nicholas Dantzker</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bursitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

